

**DRUG PRIOR AUTHORIZATION COMMITTEE**

**June 20, 2019**

**Agenda**

Missouri Coalition for Community Behavioral Healthcare  
Lower Level CEO Room, 221 Metro Drive  
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:15	Minutes Review	Discussion/Approval
10:15 - 10:25	Pharmacy Program/ Budget Update	Elizabeth Short
10:25 - 10:35	DUR Update	Mark Roaseau

**Old Business**

10:35 – 10:40	<b>A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)</b>	Mark Roaseau
---------------	--	--------------

**New Business**

10:40 – 11:00	<b>B. Proposed Actions - New Drug/Product Review</b> (See website and Attached Summary)	Mark Roaseau
---------------	--	--------------

- i. Open Access**
- ii. Clinical Edit/Step Therapy**
- iii. PDL Products**
- iv. Prior Authorization**
  - Discussion
  - Public Hearing
  - Decision

11:00 – 12:00	<b>C. <u>Clinical Edits</u></b>	
	<b>I. Antianxiety Benzodiazepine Clinical Edit</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul>	
	<b>II. Butalbital Combinations without Codeine Clinical Edit</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul>	
	<b>III. Butalbital Combinations Excessive Therapy Fiscal Edit</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul>	
	<b>IV. Equetro Clinical Edit</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul>	
	<b>V. Gamifant Clinical Edit</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul>	
	<b>VI. Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul>	

- VII. **Oxervate Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- VIII. **Parathyroid Hormone and Bone Resorption Suppression Related Agents Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision
- IX. **Selzentry Clinical Edit**
  - Discussion
  - Public Hearing
  - Decision

12:00 – 2:00

**D. Preferred Drug List (PDL)**

- I. **Amylin Analogs**
  - Discussion
  - Public Hearing
  - Decision
- II. **Antihyperuricemic Agents**
  - Discussion
  - Public Hearing
  - Decision
- III. **Bile Salts Agents**
  - Discussion
  - Public Hearing
  - Decision
- IV. **Benign Prostatic Hyperplasia Agents**
  - Discussion
  - Public Hearing
  - Decision
- V. **Bone Ossification, Bisphosphonate Agents**
  - Discussion
  - Public Hearing
  - Decision
- VI. **Cephalosporins Antibiotics - Oral**
  - Discussion
  - Public Hearing
  - Decision
- VII. **Colony Stimulating Factors**
  - Discussion
  - Public Hearing
  - Decision
- VIII. **DPP-IV (Dipeptidyl Peptidase-4) Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- IX. **Electrolyte Depleters, Phosphate Lowering Agents**
  - Discussion
  - Public Hearing
  - Decision
- X. **Electrolyte Depleters, Potassium Lowering Agents**
  - Discussion
  - Public Hearing
  - Decision

- XI. **Erythropoiesis Stimulating Agents**
  - Discussion
  - Public Hearing
  - Decision
- XII. **Fluoroquinolones – Oral**
  - Discussion
  - Public Hearing
  - Decision
- XIII. **GI Antibiotics – Oral:**
  - Discussion
  - Public Hearing
  - Decision
- XIV. **GLP-1 Receptor Agonists**
  - Discussion
  - Public Hearing
  - Decision
- XV. **Growth Hormones and Growth Factors**
  - Discussion
  - Public Hearing
  - Decision
- XVI. **Hepatitis C Therapy**
  - Discussion
  - Public Hearing
  - Decision
- XVII. **Insulins – Non-Analogs**
  - Discussion
  - Public Hearing
  - Decision
- XVIII. **Insulins – Long Acting**
  - Discussion
  - Public Hearing
  - Decision
- XIX. **Insulins – Mix**
  - Discussion
  - Public Hearing
  - Decision
- XX. **Insulins – Rapid Acting**
  - Discussion
  - Public Hearing
  - Decision
- XXI. **Macrolides**
  - Discussion
  - Public Hearing
  - Decision
- XXII. **Methotrexate Products**
  - Discussion
  - Public Hearing
  - Decision
- XXIII. **Multiple Sclerosis (MS) Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXIV. **Oral Anti-Diabetics: Alpha-Glucosidase Inhibitors**
  - Discussion
  - Public Hearing
  - Decision

- XXV. **Oral Anti-Diabetics: Biguanides**
  - Discussion
  - Public Hearing
  - Decision
- XXVI. **Oral Anti-Diabetics: Combinations**
  - Discussion
  - Public Hearing
  - Decision
- XXVII. **Oral Anti-Diabetics: Meglitinides**
  - Discussion
  - Public Hearing
  - Decision
- XXVIII. **Oral Anti-Diabetics: Thiazolidinediones**
  - Discussion
  - Public Hearing
  - Decision
- XXIX. **Penicillins**
  - Discussion
  - Public Hearing
  - Decision
- XXX. **Second Generation Sulfonylureas**
  - Discussion
  - Public Hearing
  - Decision
- XXXI. **Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors**
  - Discussion
  - Public Hearing
  - Decision
- XXXII. **Systemic Immunomodulators, CAPS Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXXIII. **Targeted Immune Modulators**
  - Discussion
  - Public Hearing
  - Decision
- XXXIV. **Tetracyclines**
  - Discussion
  - Public Hearing
  - Decision
- XXXV. **Thrombocytopenia Agents**
  - Discussion
  - Public Hearing
  - Decision
- XXXVI. **Urinary Tract Antispasmodics**
  - Discussion
  - Public Hearing
  - Decision
- XXXVII. **Vaginal Antibiotics**
  - Discussion
  - Public Hearing
  - Decision

**E. Preferred Drug List Classes for Sept/Oct**

- i. Process Discussion
- ii. Therapeutic classes/to be announced at the meeting

1:00

**LUNCH**

2:00-2:15

**Other Business**

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly*

**NEXT MEETING: September 19, 2019  
Harry S Truman Building, 301 W High St, Room 490-492  
Jefferson City, MO**